The researchers measured biochemical cardiovascular risk factors in 371 patients before surgery and again 12 months after gastric bypass surgery, adding three new tests to the standard panel of cholesterol and triglyceride assays. They saw improvements in all cardiac risk factors, with the most significant improvements for triglycerides and one of the new tests: C-reactive protein.
"Medication with statins - the most effective non-surgical treatment available - lowers C-reactive protein by about 16 percent. But we found that gastric bypass lowered it by 50 percent. That's a pretty significant improvement over what's been considered state-of-the-art therapy," said senior author John Morton, MD, assistant professor of surgery at the Stanford School of Medicine and director of bariatric surgery at Stanford Hospital.
Lead author Brandon Williams, MD, a general surgery resident, will present the study's findings at 7:45 a.m. Eastern time on June 30 at the annual scientific meeting of the American Society for Bariatric Surgery, held June 26-July 1 in Orlando, Fla.
Gastric bypass surgery, the most common form of weight-loss surgery, reduces the stomach's size to limit the amount of food intake and bypasses more than 35 inches of the approximately 20-foot-long small intestine, which cuts down on nutrient absorption.
The number of gastric bypass surgeries has shot up in recent years, increasing from 29,000 procedures in 1999 to about 141,000 in 2004, according to the bariatric surgery society. The procedure poses about a 2
Contact: Rosanne Spector
Stanford University Medical Center